From stratification to therapy
Metabolic pathways rather than organs
First universal digital twin in oncology paving the way for effective oncology based on pan-cancer stratification
More patients can benefit from your therapy
pharmaceuticals : You have an anti-cancer targeted molecule in clinical phase 1. or a drug already on the market. Let’s work together to identify all possible repositioning opportunities.
Biotech companies : You have an anti-cancer targeted molecule in clinical phase 1. Let’s work together to identify all possible repositioning opportunities.
Our product range
Repositioning and repurposing of targeted therapies
They support us
- UPCité
- CNRS
- INCA
- Erganéo
- Paris Biotech Santé
- France 2030